. Ultrastructure ofpituitary adenoma. Note sparse peripheral neurosecretory granules of small diameter (less than 150 nm) (arrow) x 6600
Postoperatively the patient became euthyroid and has remained so for 2 years without specific treatment. Her galactorrhoea has ceased but she remains growth hormone adrenocorticotrophic hormone and oestrogen deficient: during a pituitary reassessment three months postoperatively using glucagon stimulation, serum cortisol levels failed to rise above 80 nmol/1. The response of the pituitary to gonadotrophin releasing hormone (GnRH 100 JLg intravenously) showed that gonadotrophin secretion had been preserved (follicle-stimulating hormone levels rising from 3.7 to 5.3 UIl, luteinizing hormone from 3.7 to 9.0 UIl) but the plasma oestradiol was less than 125 pmol/l,
Discussion
Thyrotoxicosis due to a thyrotrophinoma may be diagnosed only where there is: (a) biochemical evidence of thyrotoxicosis; (b) absence of ophthalmology and of thyroidstimulating antibodies; (c) elevated TSH levels despite thyrotoxicosis; (d) the presence of a pituitary tumour with histological evidence of thyrotrophs; (e) resolution of the thyrotoxicosis following removal of the tumour'". In our patient, TSH levels were not estimated until after treatment for thyrotoxicosis had been started; nevertheless, at a time when thyroid function tests were normal the basal TSH level was elevated and there was a further rise in response to TRH stimulation. Such a pattern of TSH secretion would be very unusual in a patient with primary thyrotoxicosis but is compatible with some reports on the behaviour of thyrotrophinornas". Our patient also satisfies criteria (a),(b), (d) and (e) above; in particular the pattern of granulation seen with electron-microscopy in this case is typical of thyrotrophs and would not be likely to occur in lactotrophs".
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Several groups have demonstrated the value of measuring a-subunit levels in these patients, since thyrotrophinomas seem to secrete this material in greater amounts than !3_TSH1,3,5.S. The basal level of a-subunit in the patient's serum was elevated and rose further after TRH injection, suggesting that a-subunit production could respond to hypothalamic releasing factors. This pattern differs from that described by a number of other authors 1 ,9,10. The association of a thyrotrophinoma with hyperprolactinaemia and amenorrhoea is well documented. In most cases the level of serum prolactin is only mildly elevated 2 -5, although in our case there was quite considerable hyperprolactinaemia. However, there was no histological evidence of lactotrophs in the tumour and it is possible that the hyperprolactinaemia resulted from interference with pituitary stalk function. considered to be a benign 'syncytial endometritis'. It is now recognized that PSST is a potentially lethal disease and that it is characterized by cytotrophoblastic cells with less syncytiotrophoblast than is found in choriocarcinoma", With further experience 42 cases of PSTI have been reported, of which four have been observed following a hydatidiform mole". We describe the case of a young woman with a malignant drug resistant PSTI following a hydatidiform mole. In this instance, management was guided by the use of antibody imaging with a monoclonal antibody to human chorionic gonadotrophin meG).
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Case report
A 19-year-oldwoman, of Pakistani origin, had a normal birth in June 1984, and presented elsewhere in October 1985 following two months amenorrhoea. At this time a pregnancy test was positive, and uterine ultrasound examination was consistent with a hydatidiform mole. Suction evacuation and subsequent histology revealed a complete hydatidiform mole.
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The Royal Society of Medicine a -"~c yclophosphamide and vincristine), and then a modification of this regimen in which cis-platinum and etoposide were substituted for cyclophosphamide and vincristine.
Despite three months of chemotherapy, her serum HCG did not fall below 90 i. u./l (normal < 5). She was staged using pelvic ultrasound and computed whole body tomography. This showed an enlarged uterus, with no other disease. In order to demonstrate the source ofHCG production, 300 p.g of mouse monoclonal anti·HCG antibody labelled with 3 mCi of 111. indium ('ITHA)5 was injected intravenously. Gamma camera imaging after 14 and 38 h was carried out, assisted by the use of axial emission computed tomography. This demonstrated an HCG producing tumour in the uterus, but there was no evidence of metastasis at any other site (Figure 1 ). Hysterectomy was performed and her HCG fell to normal. Histological examination showed a PSTT, which was supported by the immunocytochemical localization ofHCG and human placental lactogen (HPLf. She was subsequently treated with adjuvant etoposide, cis-platinum, methotrexate, and actinomycin-D for three months. She remains asymptomatic and her HCG is still normal.
Ant
In contrast to invasive mole or choriocarcinoma following a hydatidiform mole, PSTT is usually resistant to chemotherapy, and total surgical removal offers the best chance of cure", This case illustrates the fact that the diagnosis of PSTT should be considered in poorly responding post mole trophoblastic tumours.
When selecting patients for surgical resection of a drug resistant trophoblastic tumour it is desirable to know that viable tumour is confined to the uterus. CT and ultrasound do not reliably distinguish viable from dead tumour and an enlarged uterus may persist after eradication of post mole tumours (J E Boultbee, personal communication). Imaging with anti·HCG antibody helped to resolve the problem in this case of PSTT as it has in drug resistant choriocarcinoma", More HPL than HCG can be demonstrated by immunocytochemistry in the cells ofPSTT and would seem to be a more promising targeting agents. However, in this case immunoscintigraphy with l11·indium·labelled anti·HCG antibody, with its novel TTHA linkage, gave good localization and this is the first report of the clinical use of the reagent. Figure 1 . a, Anterior gamma camera image ofthe lower abdomen 38 h after anti·HCG antibody administration. The tumour is located by accumulation of radiolabelled antibody in the uterus (arrowed).
Activity above the tumour is non-specific uptake of III-indium in the vertebral bodies and the right lobe of the liver (top left). b, Axial emission computed tomogram at the level of the uterus. This demonstrates that the radiolabelled antibody is principally located anteriorly in the uterus (arrowed) and not in the posterior bony structures
Menstruation then returned to normal until May 1986, when it ceased. She was referred to this department in September 1986 with a slowly rising serum HCG concentration and without vaginal blood loss. Physical examination, routine haematological and biochemical indices were all normal. Ultrasound examination of the uterus was consistent with a trophoblastic tumour and excluded pregnancy. There was no evidence of disease elsewhere.
At Charing Cross Hospital, patients with trophoblastic tumours are classified according to the risk of developing resistance to chemotherapy. Using the modified Charing Cross scoring system", she was allocated to a 'low risk' category and commenced on methotrexate with folinic acid rescue. Her serum HCG concentrations failed to fall. She was therefore sequentially treated as 'medium risk' (with etoposide, methotrexate, hydroxyurea, 6-mercaptopurine, and actinomycin D), 'high risk' (with etoposide, methotrexate, actinomycin D,
